This article is more than 5 years old. Information may no longer be current.

FDA approves next-generation EES

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Boston Scientific has announced that its Promus Premier everolimus-eluting platinum chromium stent system has received FDA approval for the treatment of CAD.

The everolimus-eluting stent (EES) will launch immediately in the United States. It features a unique customized platinum chromium alloy stent architecture and the everolimus drug with a biocompatible, fluorinated co-polymer and an enhanced stent delivery system, according to a press release.

The first implantation of the stent is scheduled to be performed by Martin B. Leon, MD, at the Center for Interventional Vascular Therapy at Columbia University Medical Center/New York-Presbyterian Hospital.

 

Martin B. Leon

“Perhaps the most impressive benefit of the Promus Premier Stent System is its unparalleled visibility, which combined with enhanced customized stent architecture, leads to an advance in currently available durable polymer [drug-eluting stents],” Leon said in the release.

The EES is available in a matrix of 94 sizes, ranging in diameter from 2.25 mm to 4.0 mm and lengths of 8 mm to 38 mm on both the Monorail and Over-the-Wire catheter platforms.

Previously, the stent received a CE mark in February 2013.